Fulcrum Equity Management’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Fulcrum Equity Management’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-88,716	Closed	-$4.56M	–	186
2021 Q1	$4.56M	Buy	88,716 +22,834	+35%	+$1.25M	1.8%	11
2020 Q4	$3.27M	Sell	65,882 -1,133	-2%	-$50.9K	1.3%	21
2020 Q3	$2.61M	Buy	67,015 +18,642	+39%	+$760K	1.21%	22
2020 Q2	$2.09M	Buy	+48,373	New	+$1.85M	0.99%	15

Other funds holding BBC

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Fulcrum Equity Management's BBC Position: Q2 2021 in Review

Fulcrum Equity Management sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q2 2021, closing a stake of 88,716 shares — an estimated $4.56M sold.

Fulcrum Equity Management first reported a position in BBC in Q2 2020 and held it in 4 quarters. The position peaked at $4.56M in Q1 2021. 19 funds tracked by Wall St. Rank hold BBC as of Q2 2021.

Fulcrum Equity Management reported no remaining Virtus Biotech Clinical Trials ETF position as of Q2 2021 after selling out during the quarter.
Fulcrum Equity Management sold 88,716 Virtus Biotech Clinical Trials ETF shares in Q2 2021, an estimated $4.56M.
Fulcrum Equity Management first reported a position in Virtus Biotech Clinical Trials ETF in Q2 2020 and held it in 4 quarters.
Fulcrum Equity Management's Virtus Biotech Clinical Trials ETF position peaked at $4.56M in Q1 2021.
19 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q2 2021.

Based on Fulcrum Equity Management's 13F filing for Q2 2021, filed 15 Jul 2021.